RecruitingPhase 3NCT04928352

Nebulized Bupivacaine Analgesia for Cleft Palate Repair

Preemptive Nebulized Bupivacaine for Pain Control After Cleft Palate Repair in Children: A Randomized Double Blind Controlled Trial


Sponsor

Assiut University

Enrollment

60 participants

Start Date

Jun 14, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

In this study we introduce a potent local anesthetic; bupivacaine 0.5% in 0.5 mg/kg dose by nebulization as a preemptive analgesia to compare efficacy and safety in children with cleft palate repair.


Eligibility

Min Age: 1 YearMax Age: 7 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 0.9% saline and a drug called Bupivacaine Hydrochloride for people with cleft palate. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 7 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBupivacaine Hydrochloride

Preoperative Nebulized Bupivacaine 0.50% 0.50 mg.kg-1

OTHER0.9% saline

Preoperative nebulized same volume of saline placebo


Locations(1)

Assiut university hospital

Asyut, Assuit, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04928352


Related Trials